Early signs that it’s working… with aggressive leukemia (ALL)… the first-ever clinical trial of an AAV-delivered cancer immunotherapy. With a single injection of instructions, the body does continuous manufacturing of complex therapeutic proteins internally. Instead of continuous protein infusions, it takes a single dose and is much less expensive than current gene therapies.
“VNX-101 is designed to turn a patient’s own liver into a biofactory capable of producing GP101, a CD19/CD3 bispecific T-cell–engaging protein, following a single administration.”
“VNX-101 has achieved an important first for the field: demonstrating that a systemically delivered, one-time in vivo therapy can translate into clinical antitumor activity in patients with blood cancer and extramedullary disease.”
— Backstory of our investment
Leave a Reply